Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
- 1
- 2
Chronic Kidney Disease (Market Access Challenges Facing Chronic Kidney Disease Treatments) | Physician & Payer Forum | Brazil/Mexico | 2015
A Survey of Medical Nephrologists and Interviews with Payers Chronic kidney disease (CKD) and its underlying conditions (diabetes and hypertension) are among the top causes of disability-…
The Budgetary Impact of Diabetic Comorbidities | Physician & Payer Forum | Brazil and Mexico | 2015
A Focus on Prescribing Trends and Payer Strategy for Diabetic Macular Edema and Diabetic Nephropathy Patients with type 2 diabetes (T2D) often present with multiple comorbidities, which boosts…
Wet Age-Related Macular Degeneration (Current and Future Uptake of Anti-VEGF Agents for Wet AMD) | Physician & Payer Forum | Brazil/Mexico | 2015
How Does Cost Versus Dosing Impact Prescriber Preferences and Payer Policy? Agents that target vascular endothelial growth factor (VEGF) have expanded the treatment armamentarium in Brazil and…
Current and Emerging Small-Molecule Targeted Agents in Key Oncology Indications | Physician & Payer Forum | Brazil and Mexico | 2015
Securing Market Share and Payer Acceptance in Increasingly Crowded and Segmented Markets in Brazil and Mexico Small molecule therapies offer specific targeting of the aberrant cellular…
The Impact of Biosimilars in NHL, Breast Cancer, and Colorectal Cancer | Physician & Payer Forum | Brazil and Mexico | 2015
Physician and Payer Expectations for Changes in Treatment Algorithms Monoclonal antibodies (MAbs) have become the standard of care in the treatment of non-Hodgkin’s lymphoma (NHL), colorectal…
Biomarker-Driven Prescribing in Oncology: Stakeholder Dynamics in Brazil for Breast Cancer, NSCLC, CRC, and Malignant Melanoma | Physician & Payer Forum | Brazil and Mexico | 2014
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Brazil is highly dependent on incorporation into…
Biomarker-Driven Prescribing in Oncology: Stakeholder Dynamics in Mexico and Argentina for Breast Cancer, NSCLC, CRC and Malignant Melanoma | Physician & Payer Forum | Mexico and Argentina | 2014
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Mexico and Argentina is highly dependent on their…
COPD (Positioning of Current and Emerging Agents) | Physician & Payer Forum | Brazil and Mexico | 2014
Improvements in patient access to novel treatments for chronic obstructive pulmonary disease (COPD) in Brazil and Mexico are largely dependent on the expansion of drug coverage by local authorities…
Asthma (Positioning of Current and Emerging Agents) | Physician & Payer Forum | Brazil and Mexico | 2014
Several newly approved agents for asthma together with others seeking approval are expanding the range of therapeutic options for this disease in Brazil and Mexico. Drugs such as the inhaled…
Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome (Novel Oral Anticoagulants in LATAM – Evolving Treatments ) | Physician & Payer Forum | Brazil and Mexico | 2014
The launch of novel oral anticoagulants (NOACs), such as Bayer/Janssen’s Xarelto, Bristol-Myers Squibb/Pfizer’s Eliquis/Elicuis, and Boehringer Ingelheim’s Pradaxa/Pradaxar, in Brazil and…
Patient Access to High-Cost Therapies for CML in LATAM: How Do Payers and Physicians Shape This Crowded and Changing Market? | Physician & Payer Forum | Brazil and Mexico | 2014
The treatment armamentarium for chronic myelogenous leukemia (CML) in Brazil and Mexico includes all three currently marketed tyrosine kinase inhibitors (TKIs): Glivec (imatinib,Novartis) for newly…
The Impact of LATAM – Payer Policy on Prescribing in Non-Hodgkin’s Lymphoma and Multiple Myeloma | Physician & Payer Forum | Brazil and Mexico | 2014
Improved patient access to specialized medical care and increased use of target therapies in oncology are expanding the multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) markets in Brazil…
- 1
- 2
